Cyclical dydrogesterone in secondary amenorrhea: Results of a double-blind, placebo-controlled, randomized study

Gynecological Endocrinology

Volumn 23, Issue 11, 2007, Pages 611-618

  Panay, Nicholas ^a   Pritsch, Maria ^b   Alt, Jeannette ^c  

^a QUEEN CHARLOTTE S AND CHELSEA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Bleeding pattern; Dydrogesterone; Oligomenorrhea; Secondary amenorrhea; Withdrawal bleeding

Indexed keywords

DYDROGESTERONE; PLACEBO;

ADULT; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; ENDOMETRIUM; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MENSTRUATION; MULTICENTER STUDY; OLIGOMENORRHEA; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY AMENORRHEA; STATISTICAL SIGNIFICANCE; WITHDRAWAL BLEEDING;

ADULT; AMENORRHEA; DOUBLE-BLIND METHOD; DYDROGESTERONE; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; ESTROGENS; FEMALE; HUMANS; MENSTRUAL CYCLE; MIDDLE AGED; OLIGOMENORRHEA; PLACEBOS; PREMENOPAUSE; PROGESTERONE;

EID: 36248939235     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701582554     Document Type: Article

References (31)

1. The Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril 2004;82(Suppl 1):S33-S39.
2. Speroff L, Fritz MA. Amenorrhea. In: Speroff L, Fritz MA, editors. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005. pp 401-464.
3. De Souza MJ, Metzger DA. Reproductive dysfunction in amenorrhoeic athletes and anorexic patients: a review. Med Sci Sports Exerc 1991;23:995-1007.
4. Klentrou P, Plyley M. Onset of puberty, menstrual frequency, and body fat in elite rhythmic gymnasts compared with normal controls. Br J Sports Med 2003;37:490-494.
5. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998;147:1038-1042.
6. Gibson M. Reproductive health and polycystic ovary syndrome. Am J Med 1995;98:67S-75S.
7. Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update 2001;7:522-535.
8. Birdsall MA, Farquhar CM. Polycystic ovaries in pre and post-menopausal women. Clin Endocrinol (Oxf) 1996;44:269-276.
9. Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust N Z J Obstet Gynaecol 1994;34:67-72.
10. van der Mooren MJ, Hanselaar AGJM, Borm GF, Rolland R. Changes in the withdrawal bleeding pattern and endometrial histology during 17β-estradiol-dydrogesterone therapy in postmenopausal women: a 2-year prospective study. Maturitas 1994;20:175-180.
11. Burch DJ, Spowart KJW, Jesinger DK, Randall S, Smith SK. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17β-oestradiol. Br J Obstet Gynaecol 1995;102:243-248.
12. Ferenczy A, Gelfand MM. Endometrial histology and bleeding patterns in postmenopausal women taking sequential combined estradiol and dydrogesterone. Maturitas 1997;26:219-226.
13. Bergeron C, Fox H. Low incidence of endometrial hyperplasia with acceptable bleeding patterns in women taking sequential hormone replacement therapy with dydrogesterone. Gynecol Endocrinol 2000;14:275-281.
14. van de Weijer PHM, Scholten P, van der Mooren MJ, Barentsen R, Kenemans P. Bleeding patterns and endometrial histology during administration of low dose estradiol sequentially combined with dydrogesterone. Climacteric 1999;2:1-9.
15. Ferenczy A, Gelfand MM, van de Weijer PHM, Rioux JE. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17β-oestradiol combined with sequential 5-20 mg dydrogesterone. Climacteric 2002;5:26-35.
16. Gelfand MM, Fugère P, Bissonnette F, Wiita B, Yang H-M, Lorrain J, Ferenczy A. Conjugated estrogens combined with sequential dydrogesterone or medroxyprogesterone acetate in postmenopausal women: effects on lipoproteins, glucose tolerance, endometrial histology and bleeding. Menopause 1997;4:10-18.
17. Belsey EM, Machin D, D'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception 1986;34:253-260.
18. Battino S, Ben-Ami M, Geslevich Y, Weiner E, Shalev E. Factors associated with withdrawal bleeding after administration of oral dydrogesterone or medroxyprogesterone acetate in women with secondary amenorrhoea. Gynecol Obstet Invest 1996;42:113-116.
19. Bernard I. New progesterone derivatives active by the oral route. Bull Fed Soc Gynecol Obstet Lang Fr 1962;14:683-684.
20. Rockenschaub A. On the problem of oral therapy in menstrual disorders. Wien Klin Wochenschr 1962;74:285-287.
21. Bompiani A, Moneta E. Progestational activity of isopregnolone in cases of secondary amenorrhoea. Ann Ostet Ginecol 1962;84:607-621.
22. Tillinger KG, Diczfalusy E. Progestational activity of stereoisomeric progesterone-analogues following oral administration in amenorrhoea. Acta Endocrinol (Copenh) 1960;35:197-203.
23. Serfaty D, Nahmanovici C, Thompson N, Le Gral M. Traitement symptomatique des améorrhées secondaires par la dydrogesterone. A propos d'une étude propective et multicentrique. Gaz Med Fr 1986;93:81-84.
24. Presl J, Horsky J. Uterine bleeding as a placebo effect. Cesk Gynekol 1970;35:413-415.
25. Presl J, Bechinie K, Horsky J. The possibility of placebo effect in the progesterone test. Cesk Gynekol 1970;35:409-412.
26. Crosignani PG, Mattei AM, Maggioni P, Testa G, Negri E. Efficacy of placebo in the treatment of patients with amenorrhea. Gynecol Obstet Invest 1994;37:183-184.
27. Nakamura S, Douchi T, Oki T, Ijuin H, Yamamoto S, Nagata Y. Relationship between sonographic endometrial thickness and progestin-induced withdrawal bleeding. Obstet Gynecol 1996;87:722-725.
28. Morcos RN, Leonard MD, Smith M, Bourguet CB, Makii M, Khawli O. Vaginosonographic measurement of endometrial thickness in the evaluation of amenorrhea. Fertil Steril 1991;55:543-546.
29. Shulman A, Shulman N, Weissenglass L, Bahary C. Ultrasonic assessment of the endometrium as a predictor of oestrogen status in amenorrhoeic patients. Hum Reprod 1989;4:616-619.
30. Krassas GE. Thyroid disease and female reproduction. Fertil Steril 2000;74:1063-1070.
31. Janssen OE, Mehlmauer N, Hahn S, Offner AH, Gartner R. The high prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 2004;150:363-369.